Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 5.42%
As of Thursday, July 23, Xilio Therapeutics, Inc.’s XLO share price has surged by 5.42%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 31.64%
As of Monday, June 02, Xilio Therapeutics, Inc.’s XLO share price has dipped by 31.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 31.43%
As of Monday, June 02, Xilio Therapeutics, Inc.’s XLO share price has dipped by 31.43%, which has investors questioning if this is right time to buy.Tudor Pop
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 16.08%
As of Wednesday, May 14, Xilio Therapeutics, Inc.’s XLO share price has dipped by 16.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 17.37%
As of Wednesday, May 14, Xilio Therapeutics, Inc.’s XLO share price has dipped by 17.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | XLO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $54.5 | $252.6 | 16% |
|
| Shares Out (Mil) | 5.8 | 52.3 | 15% |
|
| Institutional Ownership | 68.5% | 92.1% | 42% |
|
| Float (Mil) | 3.8 | 40.2 | 9% |
|
| Beta | -0.09 | 0.95 | 4% |
|
| Avg Daily Volume (000s) | 25 | 455 | 22% |
|
| Price Change (52-week) |
(6.1%) | 52.9% | 40% |
|
| Growth | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 8.7% | (9.9%) | 53% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.1% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $38 | 21% |
|
| Net Income (TTM) (Mil) | ($31) | ($43) | 20% |
|
| EPS (TTM) | ($5.413) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $61 | $5 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $5 | 25% |
|
| Enterprise Value (Q1) (Mil) | ($94) | $180 | 0% |
|
| Valuation | XLO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.73 | 2.56 | 14% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XLO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.1% | 63.8% | 88% |
|
| Net Margin | (58.5%) | (67.3%) | 11% |
|
| ROA | (23.4%) | (49.8%) | 19% |
|
| ROE | (75.2%) | (55.5%) | 12% |
|
| Liabilities to Assets | 55.6% | 30.3% | 48% |
|
| F-Score | 4 | 3 | 34% |
|
Xilio Therapeutics, Inc. did not pass any screens on 7/31/2026.
